MariTide (Maridebart Cafraglutide)

MariTide, generic name maridebart cafraglutide, is an investigational obesity treatment from Amgen with one feature nothing else in the category has: it is dosed once a month. Every approved injectable GLP-1 is weekly or daily.

Its phase 2 trial, published in 2025, enrolled 592 participants across two cohorts. In the obesity cohort of 465 people, mean weight change at week 52 ranged from −12.3% to −16.2% across the dose groups, versus −2.5% on placebo. In a separate cohort of 127 people with obesity and type 2 diabetes, weight change ran −8.4% to −12.3% against −1.7% on placebo, with A1C falling 1.2 to 1.6 percentage points. The smaller weight effect in the diabetes cohort follows a pattern seen across the whole drug class.

The molecule is structurally unusual: an antibody conjugated to GLP-1 peptides, which is what stretches the dosing interval so far. Gastrointestinal adverse events were common but, the investigators noted, less frequent with dose escalation and a lower starting dose — the same lesson every drug in this category has learned.

Monthly dosing is not automatically better, and that is the misconception worth flagging. Twelve injections a year is a real adherence advantage. But a long interval also means a long tail: if a dose disagrees with you, you cannot simply skip next week, and the drug is not quickly reversible before a procedure or a pregnancy. Those trade-offs will matter once there is a label to read.

MariTide is not FDA-approved and is not available outside clinical trials. There is nothing to ask a prescriber about yet beyond trial enrollment. Our pipeline review and pipeline tracker follow the phase 3 program.